Pharsight

Drugs facing NCE-1 in 2030

1. Brexafemme patents expiration

BREXAFEMME's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8188085 SCYNEXIS Antifungal agents
Aug, 2030

(6 years from now)

US10927142 SCYNEXIS Salts and polymorphs of SCY-078
Jan, 2035

(10 years from now)

US10174074 SCYNEXIS Salts and polymorphs of SCY-078
Jan, 2035

(10 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10370406 SCYNEXIS Salts and polymorphs of SCY-078
Jan, 2035

(10 years from now)

US11534433 SCYNEXIS Antifungal agents with enhanced activity in acidic pH
Jun, 2039

(14 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jun 01, 2026
New Indication(I-903) Nov 30, 2025
Generating Antibiotic Incentives Now(GAIN) Jun 01, 2031

Drugs and Companies using IBREXAFUNGERP CITRATE ingredient

NCE-1 date: 01 June, 2030

Market Authorisation Date: 01 June, 2021

Treatment: Treatment of adult and post-menarchal pediatric females with vulvovaginal candidiasis (vvc); Reduction in the incidence of recurrent vulvovaginal candidiasis (rvvc) in adult and post-menarchal pediatr...

Dosage: TABLET;ORAL

More Information on Dosage

BREXAFEMME family patents

Family Patents

2. Cresemba patents expiration

CRESEMBA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7459561 ASTELLAS N-substituted carbamoyloxyalkyl-azolium derivatives
Oct, 2020

(3 years ago)

US6812238 ASTELLAS N-substituted carbamoyloxyalkyl-azolium derivatives
Oct, 2025

(1 year, 4 months from now)

US10812238 ASTELLAS Configurable reference signals
Oct, 2025

(1 year, 4 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6812238

(Pediatric)

ASTELLAS N-substituted carbamoyloxyalkyl-azolium derivatives
May, 2026

(1 year, 10 months from now)

US10603280 ASTELLAS Active ingredient containing stabilised solid medicinal forms and methods for the production thereof
Sep, 2027

(3 years from now)

US10206879 ASTELLAS Active ingredient containing stabilised solid forms and method for the production thereof
Sep, 2027

(3 years from now)

US10603280

(Pediatric)

ASTELLAS Active ingredient containing stabilised solid medicinal forms and methods for the production thereof
Mar, 2028

(3 years from now)

US10206879

(Pediatric)

ASTELLAS Active ingredient containing stabilised solid forms and method for the production thereof
Mar, 2028

(3 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-90) Mar 06, 2022
New Chemical Entity Exclusivity(NCE) Mar 06, 2020
Orphan Drug Exclusivity(ODE-305) Mar 06, 2022
Orphan Drug Exclusivity(ODE-458) Dec 08, 2030
New Patient Population(NPP) Dec 08, 2026
Orphan Drug Exclusivity(ODE-454) Dec 08, 2030
ODE*(ODE*) Mar 06, 2022
Pediatric Exclusivity(PED) Jun 08, 2031
Generating Antibiotic Incentives Now(GAIN) Sep 06, 2027
Orphan Drug Exclusivity(ODE) Mar 06, 2022

Drugs and Companies using ISAVUCONAZONIUM SULFATE ingredient

NCE-1 date: 08 June, 2030

Market Authorisation Date: 22 November, 2022

Treatment: NA

Dosage: CAPSULE;ORAL; POWDER;INTRAVENOUS

More Information on Dosage

CRESEMBA family patents

Family Patents